Joel P. Bercu

1.6k total citations
45 papers, 725 citations indexed

About

Joel P. Bercu is a scholar working on Health, Toxicology and Mutagenesis, Cancer Research and Computational Theory and Mathematics. According to data from OpenAlex, Joel P. Bercu has authored 45 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Health, Toxicology and Mutagenesis, 20 papers in Cancer Research and 10 papers in Computational Theory and Mathematics. Recurrent topics in Joel P. Bercu's work include Carcinogens and Genotoxicity Assessment (20 papers), Effects and risks of endocrine disrupting chemicals (16 papers) and Computational Drug Discovery Methods (10 papers). Joel P. Bercu is often cited by papers focused on Carcinogens and Genotoxicity Assessment (20 papers), Effects and risks of endocrine disrupting chemicals (16 papers) and Computational Drug Discovery Methods (10 papers). Joel P. Bercu collaborates with scholars based in United States, United Kingdom and Germany. Joel P. Bercu's co-authors include David G. Dolan, Krista L. Dobo, Patricia A. Weideman, John Nicolette, Robert A. Jolly, Susanne Glowienke, Eric J. Morinello, Neil J. Parke, Roger D. Meyerhoff and M. Vijayaraj Reddy and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Chemical Research in Toxicology and Critical Reviews in Toxicology.

In The Last Decade

Joel P. Bercu

41 papers receiving 671 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel P. Bercu United States	20	203	201	154	102	85	45	725
Susanne Glowienke Switzerland	16	237 1.2×	172 0.9×	136 0.9×	221 2.2×	94 1.1×	28	700
Krista L. Dobo United States	20	420 2.1×	241 1.2×	289 1.9×	199 2.0×	136 1.6×	42	947
John Nicolette United States	10	209 1.0×	130 0.6×	152 1.0×	92 0.9×	35 0.4×	20	469
Angela White United Kingdom	10	180 0.9×	97 0.5×	100 0.6×	131 1.3×	49 0.6×	22	427
Laura Custer United States	16	306 1.5×	164 0.8×	213 1.4×	175 1.7×	62 0.7×	22	673
David J. Ponting United Kingdom	16	159 0.8×	328 1.6×	227 1.5×	86 0.8×	80 0.9×	37	740
Sébastien Gagné Canada	15	23 0.1×	116 0.6×	138 0.9×	24 0.2×	47 0.6×	58	649
Jeffrey C. Theiss United States	23	606 3.0×	333 1.7×	482 3.1×	23 0.2×	25 0.3×	63	1.4k
Andreas Czich Germany	19	274 1.3×	175 0.9×	293 1.9×	168 1.6×	61 0.7×	30	875
Corie A. Ellison United States	18	76 0.4×	274 1.4×	57 0.4×	51 0.5×	12 0.1×	34	749

Countries citing papers authored by Joel P. Bercu

Since Specialization

Citations

This map shows the geographic impact of Joel P. Bercu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel P. Bercu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel P. Bercu more than expected).

Fields of papers citing papers by Joel P. Bercu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel P. Bercu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel P. Bercu. The network helps show where Joel P. Bercu may publish in the future.

Co-authorship network of co-authors of Joel P. Bercu

This figure shows the co-authorship network connecting the top 25 collaborators of Joel P. Bercu. A scholar is included among the top collaborators of Joel P. Bercu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel P. Bercu. Joel P. Bercu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bercu, Joel P., Olivier Dirat, Krista L. Dobo, et al.. (2024). N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da. Regulatory Toxicology and Pharmacology. 154. 105704–105704. 7 indexed citations

Bercu, Joel P., Craig A. J. Fisher, Jedd Hillegass, et al.. (2024). Safety assessment of protein A and derivation of a parenteral health-based exposure limit. Regulatory Toxicology and Pharmacology. 153. 105700–105700.

Hasselgren, Catrin, Michelle Kenyon, Lennart T. Anger, et al.. (2024). Analysis of non-mutagenic substances in the context of drug impurity assessment – Few are potent toxicants. Regulatory Toxicology and Pharmacology. 150. 105645–105645. 1 indexed citations

Whritenour, Jessica, Joel P. Bercu, Jessica Graham, et al.. (2023). Sensitization Assessment of Extractables and Leachables in Pharmaceuticals: ELSIE Database Analysis. PDA Journal of Pharmaceutical Science and Technology. 78(4). 399–444. 3 indexed citations

Parker, Jillian A., Ernest S. Fung, Alejandra Trejo‐Martin, et al.. (2022). The utility of hERG channel inhibition data in the derivation of occupational exposure limits. Regulatory Toxicology and Pharmacology. 134. 105224–105224.

Jolly, Robert A., Joel P. Bercu, David G. Dolan, et al.. (2022). Setting impurity limits for endogenous substances: Recommendations for a harmonized procedure and an example using fatty acids. Regulatory Toxicology and Pharmacology. 134. 105242–105242. 1 indexed citations

Bercu, Joel P., Thomas H. Broschard, Catrin Hasselgren, et al.. (2022). Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls). PDA Journal of Pharmaceutical Science and Technology. 76(5). 369–383. 7 indexed citations

Graham, Jessica, Mark W. Powley, Susanne Glowienke, et al.. (2021). Calculating qualified non-mutagenic impurity levels: Harmonization of approaches. Regulatory Toxicology and Pharmacology. 126. 105023–105023. 7 indexed citations

Bercu, Joel P., George E. Johnson, Andreas Czich, et al.. (2021). Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA). Regulatory Toxicology and Pharmacology. 123. 104926–104926. 20 indexed citations

10.

Hutchinson, Richard W., et al.. (2021). Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey. Regulatory Toxicology and Pharmacology. 122. 104895–104895. 7 indexed citations

11.

Weidolf, Lars, Thomas Andersson, Joel P. Bercu, et al.. (2019). Qualification of impurities based on metabolite data. Regulatory Toxicology and Pharmacology. 110. 104524–104524. 12 indexed citations

12.

Bercu, Joel P., et al.. (2016). Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs). Regulatory Toxicology and Pharmacology. 79. S48–S56. 32 indexed citations

13.

Faria, Ellen C., et al.. (2016). Using default methodologies to derive an acceptable daily exposure (ADE). Regulatory Toxicology and Pharmacology. 79. S28–S38. 30 indexed citations

14.

Hayes, Eileen P., Robert A. Jolly, Ellen C. Faria, et al.. (2016). A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing – Operational considerations. Regulatory Toxicology and Pharmacology. 79. S39–S47. 21 indexed citations

15.

Dolan, David G., et al.. (2015). Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds. Regulatory Toxicology and Pharmacology. 72(3). 602–609. 19 indexed citations

16.

Galloway, Sheila M., et al.. (2013). Potentially mutagenic impurities: Analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities. Regulatory Toxicology and Pharmacology. 66(3). 326–335. 29 indexed citations

17.

Bercu, Joel P., et al.. (2010). Prediction of Drug Degradation Pathways leading to Structural Alerts for Potential Genotoxic Impurities. Organic Process Research & Development. 14(4). 1015–1020. 27 indexed citations

18.

Bercu, Joel P., Robert A. Jolly, Kelly M. Flagella, et al.. (2010). Toxicogenomics and cancer risk assessment: A framework for key event analysis and dose–response assessment for nongenotoxic carcinogens. Regulatory Toxicology and Pharmacology. 58(3). 369–381. 26 indexed citations

19.

Bercu, Joel P., Krista L. Dobo, Elmar Gocke, & Timothy J. McGovern. (2009). Overview of Genotoxic Impurities in Pharmaceutical Development. International Journal of Toxicology. 28(6). 468–478. 32 indexed citations

20.

Bercu, Joel P., Wherly P. Hoffman, Cindy Lee, & Daniel Ness. (2008). Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance. Regulatory Toxicology and Pharmacology. 51(3). 270–277. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact